GRNA for targeted destruction of SARS-CoV-2 genome and application of gRNA

A virus genome, sars-cov-2 technology, applied in the field of gene editing
CN112143731AActive Publication Date: 2020-12-29GUANGZHOU REFORGENE MEDICINE CO LTD
5 Cites 3 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
GUANGZHOU REFORGENE MEDICINE CO LTD
Publication Date
2020-12-29

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to gRNA for targeted destruction of an SARS-CoV-2 genome and an application of the gRNA, and belongs to the technical field of gene editing. The gRNA comprises a targeting structural domain, and a sequence of the targeting structural domain targets an S region of the SARS-CoV-2 genome. The invention also provides a gRNA expression vector for treating SARS-CoV-2 infection, a Crispr system, a composition containing the gRNA or nucleotide encoding the gRNA, and a pharmaceutical application of the gRNA expression vector, the Crispr system and the composition. The gRNA provided by the invention can destroy the Spike region of the SARS-CoV-2 genome in a targeting manner, and can be used for treating the SARS-CoV-2 infection.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the technical field of gene editing, in particular to a gRNA targeted to destroy the genome of SARS-CoV-2 virus and its application. Background technique

[0002] There are many types of coronaviruses, most of which only infect animals but sometimes mutate and infect humans. The novel coronavirus, SARS-CoV-2, is a mutated virus that can spread rapidly from person to person and can cause severe respiratory disease. It is highly contagious and harmful, and there is currently no specific drug or method that can treat the new coronavirus. Although some researchers have proposed that some antiviral drugs on the market or under research may have an inhibitory effect on the new coronavirus, their effectiveness and safety have not been proven, and further clinical research is needed. Therefore, the development of new therapeutic techniques and drugs has become an urgent need.

[0003] SARS-CoV-2 belongs to coronavirus lineage B (Bet...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More